Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform
Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute.
With our mCodes™ technology, we've unlocked protein multiplexing for pooled in vivo testing of complex biologics.
Discover how our innovative platform unlocks the next generation of complex biologics across a range of therapeutic areas.Learn More